Primary Hyperoxaluria Pipeline and Clinical Trials (2023) | Companies- OxThera, Dicerna Pharmaceuticals, Biocodex, Allena pharmaceuticals, Amarna Therapeutics, Chinook therapeutics, BridgeBio, and Others

The report titled "Primary Hyperoxaluria Pipeline Insight 2023" by DelveInsight offers extensive information on more than 8+ companies and 8+ pipeline drugs in the field of Primary Hyperoxaluria. It presents detailed profiles of these drugs, encompassing both Primary Hyperoxaluria clinical trials and nonclinical stage products. The Primary Hyperoxaluria pipeline report also includes a thorough assessment of therapeutics based on product type, stage, route of administration, and molecule type. Additionally, it highlights the inactive pipeline products in this area.

The Primary Hyperoxaluria Pipeline report provides an elaborate account of the drug, encompassing its mechanism of action, Primary Hyperoxaluria clinical trials studies, Primary Hyperoxaluria NDA approvals (if any), and product development endeavors such as technology advancements, collaborations pertaining to Primary Hyperoxaluria, licensing, mergers and acquisitions, funding, designations, and other relevant details concerning the product.

To explore more information on the latest breakthroughs in Primary Hyperoxaluria Pipeline treatment landscape of the report, click here @ Primary Hyperoxaluria Pipeline Outlook- https://www.delveinsight.com/sample-request/primary-hyperoxaluria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Primary Hyperoxaluria Pipeline Report
• Over 8+ Metastatic Prostate Cancer companies are evaluating 8+ Primary Hyperoxaluria pipeline therapies in various stages of development, and their anticipated acceptance in the Primary Hyperoxaluria market would significantly increase market revenue.
• The leading Metastatic Prostate Cancer companies are working in the market such as OxThera, Dicerna Pharmaceuticals, Biocodex, Allena pharmaceuticals, Amarna Therapeutics, Chinook therapeutics, BridgeBio, and Others.
• Emerging Metastatic Prostate Cancer pipeline therapies in various stages of development include Oxalobacter formigenes, Nedosiran (DCR-PHXC), ALLN-177, Stiripentol (Biocodex), and others
• Dicerna Pharmaceutical's Nedosiran (formerly referred to as DCR-PHXC) is an advanced therapy utilized with the company's GalXC technology to treat patients with PH. It inhibits the lactate dehydrogenase (LDH) enzyme in the final common step of this pathway and thereby attempts to prevent this overproduction of oxalate. This LDH enzyme inhibition occurs specifically in the liver due to the incorporation of GalNAc targeting ligands in nedosiran that bind specifically to the asialoglycoprotein receptors (ASGPR) on hepatic cell surfaces. It is an RNAi therapy in development for the treatment of all three known types of PH. The company is evaluating nedosiran in the PHYOX clinical program.
• ALLN-177 is a crystalline formulation of the enzyme oxalate decarboxylase to specifically degrade oxalate within the GI tract, allowing for its removal from the body through the bowel. This mechanism of action reduces the accumulation of oxalate in the body, limiting the burden on the kidney to filter and then excrete it in the urine. The drug is a first-in-class oral enzyme therapy in late-stage clinical development for the treatment of hyperoxaluria. The drug is being developed in Phase II for PH by Allena Pharmaceutical.
• Biocodex's Stiripentol is an anticonvulsant drug used in treating epilepsy as an adjunct therapy along with Clobazam and Valproic acid. This drug is currently approved in the US, Canada, and European countries as oral tablets marketed as Diacomit for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older. In June 2020, orphan designation number EU/3/20/2290 was granted by the European Commission to Biocodex for stiripentol to treat PH and in February 2021, Stiripentol was granted an Orphan Drug designation by the US FDA for the treatment of PH.
• Nedosiran (formerly referred to as DCR-PHXC) is the only RNAi drug candidate in development for primary hyperoxaluria (PH) types 1, 2 and 3 and is Dicerna's most advanced product candidate utilizing the proprietary GalXC™ RNAi technology platform. Nedosiran is designed to inhibit the lactate dehydrogenase (LDH) enzyme - an enzyme that catalyzes the final step in a common pathway resulting in oxalate overproduction in patients with PH1, PH2 and PH3. Dicerna is evaluating the safety and efficacy of nedosiran in Phase III clinical trial in patients with all known forms of PH as part of its PHYOX clinical development program. In November 2014, Arbutus signed a licensing and collaboration agreement with Dicerna Pharmaceuticals, Inc., to utilize the proprietary LNP delivery technology exclusively in Dicerna's primary hyperoxaluria type 1 (PH1) development program.

Primary Hyperoxaluria Overview
Primary hyperoxaluria (PH) is a group of rare genetic metabolic disorders that are characterized by the accumulation of a substance known as oxalate in the kidneys and other organ systems of the body. Affected individuals lack functional levels of a specific enzyme that normally prevents the accumulation of oxalate. There are three main types of PH - PH types I, II, and III - differentiated by the specific enzyme that is deficient.

For further information, refer to the detailed Primary Hyperoxaluria Unmet Needs, Metast Primary Hyperoxaluria Market Drivers, and Primary Hyperoxaluria Market Barriers, click here for Primary Hyperoxaluria Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/primary-hyperoxaluria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Primary Hyperoxaluria Emerging Drugs Profile
• Oxabact: OxThera
• DCR-PHXC: Dicerna Pharmaceuticals

Primary Hyperoxaluria Pipeline Therapeutics Assessment
There are around 8 or more prominent companies engaged in the development of treatments for Primary Hyperoxaluria. Among these companies, OxThera stands out as the one with Primary Hyperoxaluria drug candidates in the most advanced stage, specifically Phase III.

Primary Hyperoxaluria Pipeline Therapeutics Assessment
• Primary Hyperoxaluria Assessment by Product Type
• Primary Hyperoxaluria by Stage and Product Type
• Primary Hyperoxaluria Assessment by Route of Administration
• Primary Hyperoxaluria by Stage and Route of Administration
• Primary Hyperoxaluria Assessment by Molecule Type
• Primary Hyperoxaluria by Stage and Molecule Type

Request a sample and discover the recent advances in Primary Hyperoxaluria Ongoing Clinical Trial Analysis and Medications, click here @ Primary Hyperoxaluria Treatment Landscape- https://www.delveinsight.com/sample-request/primary-hyperoxaluria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Some of the Companies in the Primary Hyperoxaluria Market Therapeutics Market include-
OxThera, Dicerna Pharmaceuticals, Biocodex, Allena pharmaceuticals, Amarna Therapeutics, Chinook therapeutics, BridgeBio, and Others

Emerging Primary Hyperoxaluria Drugs
• DCR-PHXC: Dicerna Pharmaceuticals
• Oxabact: OxThera

Dive deep into rich insights for drugs for Primary Hyperoxaluria Pipeline, click here @ Primary Hyperoxaluria Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/primary-hyperoxaluria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Primary Hyperoxaluria Pipeline Report
• Coverage- Global
• Primary Hyperoxaluria Companies- OxThera, Dicerna Pharmaceuticals, Biocodex, Allena pharmaceuticals, Amarna Therapeutics, Chinook therapeutics, BridgeBio, and Others.
• Primary Hyperoxaluria Pipeline Therapies- Oxalobacter formigenes, Nedosiran (DCR-PHXC), ALLN-177, Stiripentol (Biocodex), and others
• Primary Hyperoxaluria Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Primary Hyperoxaluria Mergers and acquisitions, Primary Hyperoxaluria Licensing Activities @ Primary Hyperoxaluria Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/primary-hyperoxaluria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Primary Hyperoxaluria: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Oxabact: OxThera
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. Stiripentol: Biocodex
11. Drug profiles in the detailed report…..
12. Preclinical stage products
13. CHK-336: Chinook therapeutics
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Primary Hyperoxaluria Key Companies
17. Primary Hyperoxaluria Key Products
18. Primary Hyperoxaluria- Unmet Needs
19. Primary Hyperoxaluria- Market Drivers and Barriers
20. Primary Hyperoxaluria- Future Perspectives and Conclusion
21. Primary Hyperoxaluria Analyst Views
22. Primary Hyperoxaluria Key Companies
23. Appendix

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

This release was published on openPR.